Genmab A/S Just Beat EPS By 29%: Here's What Analysts Think Will Happen Next
Genmab A/S shares rose 7.6% to kr.1,999 after interim results. The company reported statutory profit of US$5.68 per share, 29% above forecast, while revenue of US$2.0b matched expectations. Analysts raised 2026 revenue to US$4.48b and EPS to US$12.14, but kept the price target at kr.2,407.
How this was made
The 30-second read
Why it matters
Analysts upgraded 2026 revenue and EPS after the interim beat, but kept the consensus price target flat, implying optimism improved earnings visibility without changing valuation assumptions. The forecast also expects revenue growth to slow versus the prior five-year rate.
Market read
Traders can use the estimate direction (up) versus valuation (unchanged PT) to gauge whether the market is likely to continue rewarding the stock or revert to slower-growth expectations.
What to watch
The article emphasizes consensus averages and target range, but does not detail pipeline milestones, trial readouts, or management guidance that could drive a true re-rating.
Background
The piece summarizes Genmab’s interim results and the resulting consensus forecast updates for 2026, including revenue, EPS, and analyst price targets.
Ticker impact
Genmab reported interim results with statutory profit per share 29% above forecast, prompting analyst upgrades to 2026 revenue and EPS.
Near-term upside may be capped unless subsequent guidance or trial/product catalysts justify a higher valuation; focus on whether estimate upgrades broaden beyond EPS.
The newest concrete facts are the interim beat (profit per share +29% vs forecast) and the direction of analyst estimate changes (revenue and EPS up), while the lack of change to the consensus price target suggests the market may already price the beat.
Market effects
Signals that analyst modeling for oncology biotech may be adjusting modestly after interim beats, but without a valuation reset.
Primarily affects European biotech sentiment and positioning around interim-report season.
Limited spillover beyond biotech peers because the article centers on consensus estimate revisions for one issuer.
Counterpoint
Unchanged consensus price target suggests the beat may not change long-term intrinsic value; the stock reaction could fade if growth decelerates as forecast.
Key entities
- companyGenmab A/S
Subject of the article, with interim results beating EPS expectations and triggering analyst estimate upgrades.
- market_participants19 analysts
Number of analysts contributing to the stated 2026 consensus revenue and EPS forecasts.
